Research Analysts Offer Predictions for PRCT Q1 Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Stock analysts at William Blair dropped their Q1 2025 earnings estimates for shares of PROCEPT BioRobotics in a note issued to investors on Tuesday, February 25th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of ($0.48) for the quarter, down from their previous forecast of ($0.38). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.94) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%.

Other equities analysts have also issued reports about the stock. Wells Fargo & Company restated an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley lowered their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday. Truist Financial reaffirmed a “buy” rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday. Finally, Jefferies Financial Group started coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They set a “hold” rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $94.29.

PROCEPT BioRobotics Trading Down 4.5 %

PRCT opened at $65.02 on Friday. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics has a 52 week low of $45.20 and a 52 week high of $103.81. The business’s 50 day moving average is $75.25 and its two-hundred day moving average is $79.94. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of -33.34 and a beta of 1.03.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 26,423 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the transaction, the chief executive officer now owns 152,762 shares in the company, valued at approximately $14,851,521.64. The trade was a 14.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Alaleh Nouri sold 28,092 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in shares of PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company’s stock worth $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company’s stock valued at $413,907,000 after purchasing an additional 297,075 shares during the period. Alliancebernstein L.P. boosted its holdings in PROCEPT BioRobotics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company’s stock worth $141,110,000 after buying an additional 218,148 shares in the last quarter. Wellington Management Group LLP grew its position in PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company’s stock worth $120,051,000 after buying an additional 416,819 shares during the period. Finally, State Street Corp increased its holdings in PROCEPT BioRobotics by 5.9% in the third quarter. State Street Corp now owns 1,179,514 shares of the company’s stock valued at $94,503,000 after buying an additional 66,175 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).